Highlights of This Issue 1145

REVIEW

1147 Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Arthur Winer, Sylvia Adams, and Paolo Mignatti

SMALL MOLECULE THERAPEUTICS

1156 ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment

1167 APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongquan Su, Larry A. Gross, William G. Rice, and Stephen B. Howell

1177 APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells
Andrea Local, Hongying Zhang, Khalid D. Benbatoul, Peter Folger, Xia Sheng, Cheng-Yu Tsai, Stephen B. Howell, and William G. Rice

1187 Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft
Giovanni E. Lombardo, Valentina Maggisano, Marilena Celano, Donato Cosco, Chiara Mignogna, Federica Baldan, Saverio M. Lepore, Lorenzo Allegri, Sonia Moretti, Cosimo Durante, Giuseppe Damante, Massimo Fiesta, Diego Russo, Stefania Bulotta, and Ettore Puxeddu

1196 Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting
Buddhadev Layek, Tanmoy Sadhukha, Jayanth Panyam, and Swayam Prabha

1207 The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts
Cindy R. Timme, Barbara H. Rath, John W. O’Neill, Kevin Camphausen, and Philip J. Tofton

1217 Tetrandrine (TET) Induces Death Receptors Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis
Gauri Shishodia, Sweaty Koul, Qin Dong, and Hari K. Koul

1229 Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation
Min-Bin Chen, Yuan-Yuan Liu, Zhao-Yu Xing, Zhi-Qing Zhang, Qin Jiang, Pei-Hua Lu, and Cong Cao

1240 Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase

LARGE MOLECULE THERAPEUTICS

1251 Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
Maire F. Osborn, Andrew H. Coles, Diane Colebiowski, Dimas Echeverria, Michael P. Mozammi, Jonathan K. Watts, Miguel Sena-Esteves, and Anastasia Khvorova

1259 Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Sofie Ellebæk Pollmann, Valerie S. Calvert, Shutui Rao, Simina M. Boca, Subha Madhavan, Ivan D. Horak, Andreas Kjar, Emanuel F. Petricoin, Michael Kragh, and Thomas Tuxen Poulsen

1271 IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
Yelena Kovtun, Paul Noordhuis, Kathleen R. Whiteman, Krystal Watkins, Gregory E. Jones, Lauren Harvey, Katharine C. Lai, Scott Portwood, Sharenne Adams, Callum M. Sloss, Gerrit Jan Schuurhuis, Gert Ossenkopppele, Eunice S. Wang, and Jan Pinkas
# Table of Contents

## CANCER BIOLOGY AND TRANSLATIONAL STUDIES

### 1280  The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer  

### 1291  Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer  
Sen Xu, Zongyuan Yang, Ping Jin, Xin Yang, Xiaoting Li, Xiao Wei, Ya Wang, Sixiang Long, Taoran Zhang, Gang Chen, Chaoyang Sun, Ding Ma, and Qinglei Gao

### 1303  Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling  
Satoshi Inoue, Hiroki Ide, Taichi Mizushima, Guiyang Jiang, George J. Netto, Momokazu Gotoh, and Hiroshi Miyamoto

## COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMarkers

### 1315  Analysis of HSP27 and the Autophagy Marker LC3B⁺ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients  

### 1324  Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial  
Vasiliki Pelekanou, William E. Barlow, Zeina A. Nahleh, Brad Wasserman, Ying-Chun Lo, Marie-Kristin von Wahlede, Daniel Hayes, Gabriel N. Hortobagyi, Julie Gralow, Debu Tripathy, Peggy Porter, Borbala Szekely, Christos Hatzis, David L. Rimm, and Lajos Pusztai

### 1332  BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors  
Camilla Stagni, Carolina Zamuner, Lisa Elefanti, Tiziana Zanin, Paola Del Bianco, Antonio Sommariva, Alessio Fabozzi, Jacopo Pigozzo, Simone Mocellin, Maria Cristina Montesco, Vanna Chiarion-Sileni, Arcangela De Nicolo, and Chiara Menin

## MODELS AND TECHNOLOGIES

### 1341  Mechanistic Modeling of Antibody–Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps  
Kenneth R. Durbin, Colin Phipps, and Xiaoli Liao

---

AC icon indicates AuthorChoice  
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Cover image adapted from Figure 1A, published in Osborn et al., beginning on page 1251. Here, molecular modeling has been used to generate a three-dimensional (3D) representation of a chemically modified, cholesterol-conjugated, self-delivering siRNA (hsiRNA). hsiRNAs are capable of rapid membrane association via cholesterol intercalation into lipid bilayers. These modifications enable siRNA delivery into cells that are notoriously difficult to transfect, including neurons, astrocytes, and as shown in this manuscript, primary human gliomas. Key—Dark purple: cholesterol; light purple: linker; purple: terminal 5'-phosphate; red: phosphorothioate backbone substitutions; black: 2'-O-methyl nucleotide; gray: 2'-fluoro nucleotide.
Molecular Cancer Therapeutics

17 (6)

Mol Cancer Ther 2018;17:1145-1351.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/17/6

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/17/6.
Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.